Trials
1 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior exposure to prohibited medications) and includes the following periods: * Active screening period of 6 weeks (or, up to 10 weeks for participants requiring a washout period). * Treatment period of 28 weeks consisting of a 19-week dose titration period and 9-week stable dose period. * Safety follow-up period of 4 weeks.”In the company’s words, NCT07890584 on ClinicalTrials.gov
- Other names
- upacicalcet
Other drugs for Chronic Kidney Disease (CKD)
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up1
- 22 Feb 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 22 Feb 2032 | A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | |
| Phase 3Completed | 28 Jul 2025 | Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 | |
| Phase 3Completed | 5 Aug 2025 | Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026